Prima BioMed (NASDAQ:IMMP) Shares Cross Above 50 Day Moving Average – Time to Sell?

Prima BioMed Ltd (NASDAQ:IMMP)’s stock price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.40 and traded as high as $0.41. Prima BioMed shares last traded at $0.4035, with a volume of 199,287 shares traded.

Analysts Set New Price Targets

Several research firms have recently commented on IMMP. Wall Street Zen upgraded Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. Finally, Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prima BioMed presently has an average rating of “Hold” and a consensus price target of $5.50.

Prima BioMed Trading Down 5.8%

The business has a fifty day moving average of $0.40 and a 200-day moving average of $0.98.

Hedge Funds Weigh In On Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC increased its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.